Multi-institutional Retrospective Analysis of the Inhomogeneity Correction for Radiation Therapy of Lung Cancer

DOI PDF Web Site 参考文献20件
  • MIZUNO Hideyuki
    Research Center for Charged Particle Therapy, National Institute of Radiological Sciences
  • OKAMOTO Hiroyuki
    Radiation Oncology Divisions, National Cancer Center Hospital
  • FUKUOKA Miyoko
    Department of Radiation Oncology, Tokyo Women's Medical University Hospital
  • HANYU Yuji
    Department of Radiation Oncology, Tokyo Women's Medical University Hospital
  • KUROOKA Masahiko
    Kanagawa Cancer Center
  • KOHNO Ryosuke
    Particle Therapy Division, Research Center for Innovative Oncology, National Cancer Center Hospital East
  • NISHIO Teiji
    Particle Therapy Division, Research Center for Innovative Oncology, National Cancer Center Hospital East
  • KUMAZAKI Yu
    Department of Radiation Oncology, Saitama Medical University International Medical Center
  • TACHIBANA Hidenobu
    Department of Radiation Oncology, The Cancer Institute Hospital of JFCR
  • TAKAHASHI Yutaka
    Department of Radiation Oncology, Osaka University Graduate School of Medicine
  • MORI Shinichiro
    Research Center for Charged Particle Therapy, National Institute of Radiological Sciences
  • MASAI Norihisa
    Miyakojima IGRT Clinic
  • SASAKI Koji
    Department of Radiological Technology, Gunma Prefectural Graduate School of Health Sciences

この論文をさがす

抄録

The purpose of this work is to retrospectively analyze the effect of the inhomogeneity correction using clinically treated plan of stage III non-small-cell lung cancer within multiple institutions in Japan. Twenty-five patients among five facilities of radiation therapy were registered for this study. The isocenter dose or D95 of PTV or other important values were compared with and without an inhomogeneity correction using model-based algorithm. The differences in isocenter dose were 4% average and 10% maximum for the first Anterior-Posterior opposed field plan to 40 Gy and 6% average and 11% maximum for the off-cord boost oblique field plan of 20 Gy. The differences in D95 dose were 1% average and 9% maximum for the first plan and 1% average and 6% maximum for the boost plan. D95 prescription seemed to be a superior method; however, its reliability depends on each clinical case. Additionally, maximum dose, minimum dose and mean dose for both the primary tumor and the metastatic lymph node were analyzed, and the minimum dose had the most impressive results. In some cases, the target volume had unintended underdose of more than 10%. Finally, an analysis of the organ at risk was added, and this showed no meaningful differences for the V20 of the lung and the maximum dose of the spinal cord. These results provide a standard for the effects of the inhomogeneity correction.

収録刊行物

参考文献 (20)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ